Compare Boston Scientific Corporation (BSX) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Dollar Tree, Inc. — how do they compare? Boston Scientific Corporation trades at $50.97 (market cap $74.19B), while Dollar Tree, Inc. trades at $128.1 (market cap $24.61B). The key difference: Boston Scientific Corporation is far larger — about 3× Dollar Tree, Inc.'s market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | DLTR | |
|---|---|---|
Market Cap | $74.19B | $24.61B |
Sector | Health | Health |
52-Week High | $108.14 | $141.21 |
52-Week Low | $42.63 | $85.04 |
Enterprise Value | $86.27B | $31.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
Dollar Tree (DLTR) trades at $129.37, down 1.17% today but remains in a bullish technical trend with strong support near $128. The company reported a net loss of $3.03B for 2025 due to a significant tax charge, though operating cash flow improved to $2.86B. Recent earnings have consistently beaten estimates, and a new $2.5B share repurchase program signals management confidence.
The outlook is mixed: robust cash generation and positive earnings surprises support upside, but margin pressures from tariffs and intense discount retail competition pose risks. Analyst consensus is a Buy with a $126.69 price target, slightly below current levels, indicating cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
